400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / MAPK/ERK Pathway / JNK / CEP-1347/Cep 1347游离态
CAS No.: 156177-65-0
Synonyms: KT7515;KT7515.3,9-Bis((ethylthio)methyl)-K-252a;3,9-Bis(etsm)-K-252a
CEP 1347 is an inhibitor of c-jun N-terminal kinase (JNK) signaling.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00404170 | Parkinson Disease | Phase 2 | Completed | - | United States, Connecticut ... more >> Institute for Neurodegenerative Disorders New Haven, Connecticut, United States, 06510 Collapse << |
NCT00605163 | - | - | Unknown | - | - |
NCT00040404 | Parkinson Disease | Phase 2 Phase 3 | Terminated(Unlikely to provide... more >> evidence of significant effect) Collapse << | - | - |
实验方案
技术信息
CAS号 | 156177-65-0 | 储存条件 |
|
|
分子式 | C33H33N3O5S2 | 运输 | 蓝冰 | |
分子量 | 615.76 | 别名 | KT7515;KT7515.3,9-Bis((ethylthio)methyl)-K-252a;3,9-Bis(etsm)-K-252a |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00404170 | Parkinson Disease | Phase 2 | Completed | - | United States, Connecticut ... more >> Institute for Neurodegenerative Disorders New Haven, Connecticut, United States, 06510 Collapse << |
NCT00605163 | - | - | Unknown | - | - |
NCT00040404 | Parkinson Disease | Phase 2 Phase 3 | Terminated(Unlikely to provide... more >> evidence of significant effect) Collapse << | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网